This could be huge. We'll have to wait until the peer review is finished, but if the referees see no flaws, this report from a major research institute seems as good as it gets for a pre-clinical study. A 75% reduction in mortality in such experimental work is astounding. One rarely sees such efficacy.  If apabetalone prevents or controls cytokine storms at the epigenetic level in covid patients, it probably will do also in cytokine storms complicating other clinical conditions, of which there are many!

https://www.nejm.org/doi/full/10.1056/NEJMra2026131